Comparison of once-daily alogliptin/metformin combination tablets and twice-daily anagliptin/metformin combination tablets switching from twice-daily metformin in Japanese type 2 diabetic patients
Not Applicable
- Conditions
- Type 2 diabetes
- Registration Number
- JPRN-UMIN000034951
- Lead Sponsor
- Fujisawa City Hospital
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 48
Inclusion Criteria
Not provided
Exclusion Criteria
1) Patients with DPP-4 inhibitor, GLP-1 receptor agonist, or insulin therapy 2) Patients with severe renal dysfunction (eGFR <30ml/min/1.73m2) 3) Patients with severe liver dysfunction 4) Patients with severe infection, operation, trauma 5) Patients with steroid medication 6) Patients who have pregnancy or possibilty of pregnancy, or are under lactation 7) Patients who have hypersensitivity to metformin, alogliptin, or anagliptin 8) Patients who are considered to be not eligible to the study by the doctor
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Comparing the two groups change in HbA1c over the 12-week treatment period, with a non-inferiority margin of 0.4%
- Secondary Outcome Measures
Name Time Method 1. Medication adherence 2. Fasting blood glucose (mg/dL) 3. Body weight (kg)